UNH closed at $418.09 on October 23, down 1.62% from $424.98, giving back part of the post-earnings breakout on 3.89 million shares (0.64x the 20-day average of 6.05 million) as the S&P 500 fell 0.52%, the Dow dropped 1.23%, the rose 2.21% to 19.45 and the 10-year Treasury yield edged up to 4.988%. The pullback is orderly rather than thesis-breaking: price remains 7.42% above the of $389.21, 6.68% above the of $391.87 and 16.09% above the of $360.13, with the 8.82% above the , so the golden-cross structure is intact. Momentum has cooled from overbought rather than reversed: (14) fell to 66.09 from 72.32, is still +9.769 above its +4.779 signal, but the histogram contracted to +4.990 from +5.606, the first deceleration after seven expanding sessions, and slipped to -73.59 million from -69.70 million. The fundamental engine remains the Q3 2026 beat of $4.69 versus $4.14 (+13.3%) on October 13, the second consecutive double-digit surprise after Q2's +29.8%, with FY2026 estimates at $20.589 (up from $19.812 ninety days ago) and FY2027 at $23.275 (up from $22.435) and zero downward annual revisions. At $418.09 the stock trades at 26.89x TTM earnings, 20.31x FY2026, 17.96x FY2027, 14.68x , 0.83x sales, a 1.01 and a 7.06% free-cash-flow yield, while the $478.12 mean target implies 14.4% upside and the $495 median implies 18.4%. The rate backdrop is less friendly than a day ago, with the 10-year at 4.988% and at 19.45, but the stock is 9.43% below its $461.62 52-week high and the next earnings report is 80 days away on January 12, 2027, so there is no binary event inside the one-month window. Recent news is stale (two September 28 articles) and mixed: healthcare's 46.9% six-month return and UNH's 100-million-member scale support the franchise, but the same article flags regulatory risk and CorVel's claims-integrity push highlights intensifying cost-containment competition. The rating remains BUY across all horizons, but the tactical edge is in staged accumulation into the $412-$421 shelf rather than chasing, with $403 as the structural stop.
投资判断
实时价格
$410.70
推荐分数
78%
78%
置信度
77%
77%
各期限展望
1个月
买入
短线
6个月
买入
中期
1年
买入
长期
核心催化
The Q3 beat and target-raise cluster remains the dominant fundamental catalyst, but the immediate market-moving question is whether the $414-$417 shelf holds after October 23's $425.25-to-$416.37 reversal; a break would make the post-earnings breakout look false and shift the near-term setup toward a retest of $404.04, while a hold keeps the $461.62 52-week high in play.
at 19.45 is at the top of the neutral band and the 10-year is 4.988%, so use standard rather than full size. Price at $418.09 is inside the $412-$421 entry shelf after testing $416.37 on October 23, so stage roughly two-thirds into the zone and keep one-third for a flush toward the $404.04 September 9 high; no earnings event until January 12, 2027 (80 days).
投资逻辑快照
什么情况涨
UNH's October 23 pullback to $418.09 is exactly the kind of low-volume retest that constructive breakouts need: volume was 3.89 million shares, 0.64x the 20-day average, the session low held $416.37 inside the prior $412-$421 entry zone, and price is still 7.42% above , 6.68% above and 16.09% above . The prior $396 stop was never threatened and the $461-$500 exit zone remains 10.7%-20.0% above the $416.50 entry midpoint. Fundamentals are intact: Q3 beat by 13.3% after Q2's 29.8%, FY26/FY27 estimates are up 3.9%/3.7% over 90 days with no annual downward revisions, and at 17.96x FY27 with a 1.01 and 7.06% FCF yield the stock is not expensive. Four target raises in nine days, $478.12 mean and $495 median targets, 1.98% short interest and a 0.615 beta defensive profile all support owning the pullback.
什么情况跌
The bear case is that the entire recovery is cost-driven: revenue is -0.4%, operating margin 5.82%, net margin 3.53%, and Q1 2026 grew only 0.4% year over year, so a utilization rebound has no top-line buffer. The balance sheet carries $45.78 billion net debt, a 0.74 current ratio and a 0.42 quick ratio. The tape is cooling: October 23 closed at $418.09, down 1.62% and near the $416.37 low, after a lower high at $425.25 versus $426.55; the histogram contracted to +4.990 from +5.606, fell to -73.59 million and remains below the September 11 -65.55 million level, and the 10-year at 4.988% with 19.45 caps multiple expansion. TD Cowen's $402 target is 3.9% below spot, Bernstein trimmed to $500 from $512, Q4 consensus still has three downward 30-day revisions, and the recommendation tally slipped to 6/15/5 from 7/15/4. If $416.37/$414.12 fail, the breakout was false and the stock likely retests $404.04 and the at $391.87.
A daily close below $414.12, the October 15 breakout high, would mark the October 20-22 post-earnings advance as a failed breakout; a subsequent close below $404.04 and the at $391.87 would confirm distribution and require exit.
Cost-driven recovery with no top-line cushion: revenue growth is -0.4% year over year, operating margin is 5.82% and net margin is 3.53%, so a reacceleration in medical utilization hits earnings directly with no revenue offset; Q1 2026 growth of just 0.4% year over year already demonstrated that sensitivity.
Overbought extension and consolidation risk: (14) at 66.09 has cooled but price is still 6.68% above the of $391.87 and 7.42% above the of $389.21 after an 11.49% one-month gain, and of $11.41 (2.73% of price) with 28.16% 20-day realized volatility means a 2%-3% single-session reversal can retest $404-$414 quickly.
Balance-sheet leverage and liquidity: net debt of $45.78 billion (12.2% of market cap, roughly 1.73x free cash flow), debt-to-equity of 70.43%, cash-to-debt of 0.38x, a current ratio of 0.74 and a quick ratio of 0.42 leave limited flexibility if claims costs rise faster than premium pricing.
Analyst dispersion and messy near-term estimates: targets span $380 to $529 (a $149 range), TD Cowen's $402 sits 3.9% below spot, Bernstein lowered to $500 from $512, the tally slipped to 6 Strong Buy / 15 Buy / 5 Hold, and Q4 2026 consensus of $2.261 still carries three downward 30-day revisions while Q1 2027 was trimmed over the past week.
Broad-market and volatility risk: the rose 2.21% to 19.45, the 10-year Treasury yield is 4.988%, the S&P 500 fell 0.52% and the Dow dropped 1.23% on October 23, so a sustained risk-off episode would eventually force index-level selling in even a 0.615-beta defensive leader and compress the 17.96x forward multiple.
Regulatory and policy risk: the September 28 article warns that healthcare is heavily regulated and vulnerable to rule changes, and Medicare Advantage rate updates or prior-authorization rules carry material earnings leverage against a 3.53% net margin with no dated catalyst supplied in the bundle.
接下来关注
下一次财报：2027年1月12日
The Q3 beat and target-raise cluster remains the dominant fundamental catalyst, but the immediate market-moving question is whether the $414-$417 shelf holds after October 23's $425.25-to-$416.37 reversal; a break would make the post-earnings breakout look false and shift the near-term setup toward a retest of $404.04, while a hold keeps the $461.62 52-week high in play.
信号仪表盘
决策输入
6 个信号
基本面
14.4%
距分析师均值目标空间
At $418.09 UNH trades at 26.89x trailing earnings, 20.31x the FY2026 estimate of $20.589, 17.96x the FY2027 estimate of $23.275, 14.68x , 0.83x sales, 3.62x book and a of 1.01. The 7.06% free-cash-flow yield and the roughly 3.7%-3.9% ninety-day increases in both annual estimates are what make the 1.01 credible rather than a statistical artifact. The 0.83x sales multiple looks optically cheap but is a direct consequence of -0.4% revenue growth, so it reflects a mature, claims-heavy model rather than mispricing. No peer multiples are supplied in the bundle, so a relative managed-care discount cannot be verified from this data. The re-rating has paused: the stock has slipped from 18.26x FY2027 at $424.98 to 17.96x today, and the mean analyst target of $478.12 now implies 14.4% upside versus 12.5% a day ago, while the $495 median implies 18.4% and the $529 high implies 26.5%. On absolute cash-flow and forward-earnings terms it is fairly valued to modestly cheap, with the entire margin of safety resting on continued medical-cost control rather than revenue expansion.
技术面
Bullish
趋势质量
At $418.09 price sits 7.42% above the 20-day of $389.21, 6.68% above the of $391.87 and 16.09% above the rising of $360.13, while the remains 8.82% above the , so the golden-cross alignment that has held all year is intact and still widening. October 23 printed a $425.25 intraday high that failed just below October 22's $426.55 and closed at $418.09, below the October 22 close of $424.98 but still above the October 20 breakout close of $419.26 and the October 21 low of $415.00. The stock remains 9.43% below its 52-week high of $461.62 and sits at the 78.8th percentile of its 52-week range, so this is a maturing recovery pressing toward prior resistance rather than a fresh base breakout.
财报
80天
Improving
Q3 2026 (reported October 13) of $4.69 beat the $4.14 consensus by 13.3%, a second consecutive large beat after Q2 2026's +29.8% surprise; the stock spiked to a $399.88 high but collapsed to a $372.80 low before closing at $377.76, then rallied to $424.98 by October 22 before pulling back 1.62% to $418.09 on October 23, a sequence that validates the margin-recovery thesis but also shows large sellers remain active around the print.
新闻
Mixed-Bullish
新闻基调
The Q3 beat and target-raise cluster remains the dominant fundamental catalyst, but the immediate market-moving question is whether the $414-$417 shelf holds after October 23's $425.25-to-$416.37 reversal; a break would make the post-earnings breakout look false and shift the near-term setup toward a retest of $404.04, while a hold keeps the $461.62 52-week high in play.
宏观
Neutral
4.99% 10Y / 19.5 VIX
at 19.45 sits at the top of the neutral band while the 10-year Treasury yield is 4.988%, so rate-sensitive multiple expansion is capped and a 0.615-beta defensive healthcare name is better positioned than high-multiple growth, but index-level de-risking can still pressure it.
稳定性
Stable Compounder
Core Anchor
UnitedHealth remains a Stable Compounder rather than a pure defensive: UnitedHealthcare plus Optum serves more than 100 million people, generated $26.50 billion of free cash flow for a 7.06% FCF yield on the $375.28 billion market cap, pays a 2.18% dividend covered by a 57.56% payout ratio, and carries a 0.615 beta. The counterweights are -0.4% year-over-year revenue growth, a 5.82% operating margin, a 3.53% net margin, $45.78 billion of net debt (12.2% of market cap, roughly 1.73x free cash flow), a 0.74 current ratio and a heavily regulated reimbursement environment. Twenty-day realized volatility of 28.16% and an of $11.41 (2.73% of price) mean roughly 3% daily swings are normal, and October 13's 6.8% intraday collapse from $399.88 to $372.80 proves gaps can overrun resting stops. It belongs as a Core Anchor inside a diversified healthcare sleeve at standard sizing, not as a bond substitute or a low-volatility safe haven.
分析师目标区间
均值目标
$478.12
高低目标
$380 / $529
分析师中值目标
$495.00
共识区间
$380 - $529
— 位分析师
Mean
$380$478$529
市场共识
The mean target of $478.12 implies roughly 14.4% upside from $418.09 and the median of $495 implies about 18.4%; the $529 high implies 26.5% while the $380 low sits 9.1% below the current price. The $149 high-to-low spread signals genuine disagreement about medical-cost, utilization and reimbursement assumptions rather than stale targets, and the fact that TD Cowen's $402 target sits 3.9% below spot shows a real skeptical cohort even after two consecutive breakouts. The number of price-target analysts is not supplied (the field is null), but the recommendation tally contains 26 opinions, 21 of which are Buy or Strong Buy, and target drift continues upward, with Mizuho the latest raise on October 22.
筹码脉冲
内部人信号
Neutral
净偏向
No recent activity
内部人持股
0.2%
机构持股
89.6%
解读
Two immaterial, unclassified director filings carry no directional information, so insider activity neither confirms nor undermines management's confidence in the post-earnings margin recovery.
重要活动
The bundle lists only two filings, both roughly five months old: Director Valerie C. Montgomery Rice with 43 shares dated 149 days ago and Director Frederick William McNabb III with 53 shares dated 148 days ago. Transaction type and value fields are empty, and at $418.09 those positions are worth roughly $17,978 and $22,159 respectively, which is consistent with routine director grants or small plan-related movements rather than open-market conviction. No C-suite cluster buying, no discretionary selling and no 10b5-1 sale pattern is identifiable. The filing set also changes between runs, so the insider dataset itself is unstable and should not be over-read.
市场背景
行业
Healthcare Plans
Bullish
情绪
36
跟踪股票
1
分组
industry
Healthcare Plans 行业 当前情绪为 Bullish，板块平均评分约 78 分，资金偏好与评分正在走弱，且leadership is still concentrated。
轮动线索
Healthcare Plans 行业 组内平均推荐分数在回落，说明短线资金偏好正在减弱。
当前组内偏多评级 1 只，偏空评级 0 只，可见情绪主导方向为 Bullish。
重点龙头股
相关龙头股
当前还没有其他已跟踪龙头股。
主题
Healthcare Sector Rotation
评分: 32
Bullish
Healthcare remains a relative-strength sector: the September 28 article cites a 46.9% six-month sector return that topped the S&P 500 by 25.5 percentage points, and it frames UNH as resilient at 17.6x forward earnings serving more than 100 million people. The rotation paused on October 23 as UNH fell 1.62% while the S&P 500 fell 0.52%, but UNH is still 9.43% below its 52-week high and above all major moving averages, so the trend has not broken. The article's own warning that healthcare is heavily regulated keeps the rotation qualified rather than unconditional.
With at 19.45 and the 10-year at 4.988%, defensive healthcare exposure remains a preferred allocation, even as the group's one-day leadership paused on October 23.
Healthcare returned 46.9% over six months versus the S&P 500, a 25.5 percentage point outperformance, per the September 28 article in the bundle.
UNH's scale of over 100 million people served and more than 400,000 employees gives it a defensive franchise profile that attracts allocation when the is near the top of the neutral band.
Managed Care Margin Recovery
评分: 45
Bullish
The managed-care earnings narrative has turned from utilization shock to margin normalization over the past two quarters. UNH has now delivered surprises of +29.8% in Q2 2026 and +13.3% in Q3 2026 after a -8.23% miss in Q2 2025, and FY2026 and FY2027 estimates have each risen roughly 3.7%-3.9% over ninety days with no downward revisions to either annual figure. The theme remains the strongest fundamental support for the stock, but it is a cost-control story rather than a volume story, since revenue growth is -0.4% year over year, which is why valuation stays near market average despite thin 3.53% net margins.
Two consecutive double-digit-percentage beats, upward revisions to both annual estimates, and four separate target raises in the last nine days (Piper Sandler to $504, JP Morgan to $524, RBC to $498 and Mizuho to $500 on October 22) are the concrete evidence that medical-cost trend has stabilized and that sell-side confidence in the recovery is broadening.
Q3 2026 beat consensus by 13.3% after a +29.8% beat in Q2 2026, reversing the pattern of 2025 misses and pushing FY2026 estimates to $20.589 from $19.812 ninety days ago and FY2027 to $23.275 from $22.435.
Annual estimate revisions remain net positive (2 up and 0 down for FY2026 over 30 days; 2 up and 1 down for FY2027) with 21 of 26 recommendations at Buy or better and zero formal downgrades in 90 days.
关键指标
23 项指标
市值
$375.28B
市盈率 (TTM)
26.9
远期市盈率
18.0
营收增速
-0.4%
净资产收益率
15.8%
Beta 系数
0.62
完整指标集
另外 17 项指标
估值结构
估值倍数与现金流框架。
市销率
0.8
市净率
3.6
企业价值 / EBITDA
14.7
质量与资产负债表
利润率、杠杆与流动性。
毛利率
20.0%
营业利润率
5.8%
资产负债率
70.4
流动比率
0.74x
速动比率
0.42x
仓位与价格区间
空头仓位与52周区间位置。
流通盘空头占比
2.0%
空头回补天数
3.11x
52周最高
$461.62
52周最低
$255.97
距52周高点
-9.4%
距52周低点
63.3%
公司分类
板块与行业背景。
板块
Healthcare
行业
Healthcare Plans
其他信号
自由现金流
$26501249024.00
详细分析
估值
At $418.09 UNH trades at 26.89x trailing earnings, 20.31x the FY2026 estimate of $20.589, 17.96x the FY2027 estimate of $23.275, 14.68x , 0.83x sales, 3.62x book and a of 1.01. The 7.06% free-cash-flow yield and the roughly 3.7%-3.9% ninety-day increases in both annual estimates are what make the 1.01 credible rather than a statistical artifact. The 0.83x sales multiple looks optically cheap but is a direct consequence of -0.4% revenue growth, so it reflects a mature, claims-heavy model rather than mispricing. No peer multiples are supplied in the bundle, so a relative managed-care discount cannot be verified from this data. The re-rating has paused: the stock has slipped from 18.26x FY2027 at $424.98 to 17.96x today, and the mean analyst target of $478.12 now implies 14.4% upside versus 12.5% a day ago, while the $495 median implies 18.4% and the $529 high implies 26.5%. On absolute cash-flow and forward-earnings terms it is fairly valued to modestly cheap, with the entire margin of safety resting on continued medical-cost control rather than revenue expansion.
资产负债表
Debt-to-equity of 70.43% is moderate for a large-cap health plan, but the absolute picture is heavier: total cash of $28.55 billion against total debt of $74.33 billion leaves net debt of $45.78 billion, which is 12.2% of the $375.28 billion market cap and roughly 1.73x annual free cash flow. Cash-to-debt of 0.38x and operating-cash-flow-to-debt of 0.35x show debt service is covered by internal generation but not comfortably deleveraging. Return on equity of 15.77% and return on assets of 5.24% are solid rather than exceptional. Current and quick ratios of 0.74 and 0.42 are structurally low for an insurer because of claims payables, but they leave limited cushion if claims costs outrun premium pricing. Short interest is only 1.98% of float with a 3.11 short ratio, so there is no meaningful bearish leverage embedded in the share base.
增长
Revenue growth is -0.4% year over year, so there is effectively no top-line growth in the supplied data. Reported earnings growth of +75.9% year over year and Q3 2026 of $4.69 versus $2.92 in Q3 2025 (+60.6%) show a powerful but base-assisted recovery, since the 2025 comparatives included a -8.23% surprise in Q2 2025 and only a +3.99% surprise in Q3 2025. The recovery is not uniform: Q2 2026 of $6.38 versus $4.08 was +56.4% year over year, but Q1 2026 of $7.23 versus $7.20 was only +0.4%. Sequential has fallen from $7.23 in Q1 2026 to $6.38 in Q2 and $4.69 in Q3, broadly consistent with health-plan seasonality. Consensus now looks for $2.261 in Q4 2026 and $8.176 in Q1 2027 (+13.1% versus the $7.23 actual), so the forward trajectory still requires continued margin normalization against a 5.82% operating margin.
生意质量
UnitedHealth combines the UnitedHealthcare insurance business with Optum, a services division spanning pharmacy benefits, primary care and health technology; the September 28 article in the bundle cites over 100 million people served and a workforce exceeding 400,000. Gross margin is 20.05%, operating margin 5.82%, margin 6.42% and net margin 3.53%, with of 15.77% and of 5.24%. Scale, payer-provider integration and $26.50 billion of free cash flow support a durable franchise that justifies a market-average rather than distressed multiple. Institutional ownership is 89.61% versus 0.25% insider ownership, so governance is externally dominated. The critical caveat is that razor-thin net margins mean a modest adverse claims trend can erase a large share of quarterly profit, which is precisely what the 2025 misses demonstrated.
资本配置
Cash of $28.55 billion against total debt of $74.33 billion produces $45.78 billion of net debt, roughly 1.73x annual free cash flow, so the balance sheet is levered but serviced internally; enterprise value of $424.32 billion is 1.13x market cap. The 2.18% dividend with a 57.56% payout ratio is well covered by a 7.06% free-cash-flow yield and has room to grow if cost control holds. The bundle reports $26.50 billion of free cash flow against $26.19 billion of operating cash flow, implying negligible capital expenditure, which is unusual for a company of this scale and likely reflects a definitional quirk rather than a truly capital-light model; readers should not extrapolate it. The database lists 897.59 million shares outstanding and 899.41 million float shares, a float marginally larger than shares outstanding, but supplies no share-count history or buyback authorization, so repurchase accretion or dilution cannot be assessed from this bundle.
预期修正
Annual estimate momentum remains positive and has accelerated slightly: FY2026 is $20.589 versus $20.469 a week ago and $19.812 ninety days ago (+3.9%), supported by 1 upward 7-day and 2 upward 30-day revisions with zero downward revisions to the annual figure. FY2027 is $23.275 versus $23.097 a week ago and $22.435 ninety days ago (+3.7%) on 2 upward 7-day and 2 upward 30-day revisions against a single downward 30-day revision. The nearby quarter is still messy: Q4 2026 consensus of $2.261 is up 7.5% from its $2.103 reading thirty days ago, yet it still carries 3 downward 30-day and 1 downward 7-day revision, and Q1 2027 has been trimmed to $8.176 from $8.198 a week ago. Formal actions lean positive on price targets but not on ratings: Mizuho raised to $500 from $493 on October 22 while maintaining Outperform, RBC Capital raised to $498 from $478 on October 20, JP Morgan raised to $524 from $516 on October 16 and Piper Sandler raised to $504 from $502 on October 14, against Bernstein's trim to $500 from $512 and TD Cowen's October 15 reiteration of Hold at $402. The recommendation tally is 6 Strong Buy, 15 Buy, 5 Hold, 0 Sell and 0 Strong Sell, a marginal deterioration from 7/15/4 a month ago, with zero formal upgrades, downgrades or initiations in 90 days.